Effects of quinidine on the action potential duration restitution property in the right ventricular outflow tract in patients with brugada syndrome

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2080-2086

  Ashino, Sonoko ^a   Watanabe, Ichiro ^a   Kofune, Masayoshi ^a   Nagashima, Koichi ^a   Ohkubo, Kimie ^a   Okumura, Yasuo ^a   Mano, Hiroaki ^a   Nakai, Toshiko ^a   Kunimoto, Satoshi ^a   Kasamaki, Yuji ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Action potential duration restitution; Brugada syndrome; Ibutilide; Quinidine; Ventricular fibrillation

Indexed keywords

IBUTILIDE FUMARATE; QUINIDINE GLUCONATE;

ADULT; AGED; ARTICLE; BRUGADA SYNDROME; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE FIBRILLATION; HUMAN; MALE; PROSPECTIVE STUDY; SUDDEN DEATH; TREATMENT RESPONSE;

ACTION POTENTIALS; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINIDINE; TIME FACTORS; VENTRICULAR FUNCTION, RIGHT;

EID: 80052153458     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0227     Document Type: Article

References (42)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992; 20: 1391-1396.
2. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100: 1660-1666.
3. Aiba T, Shimizu W, Hidaka I, Uemura K, Noda T, Zheng C, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: High-resolution optical mapping study. J Am Coll Cardiol 2006; 47: 2074-2085.
4. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005; 67: 367-378.
5. Omichi C, Zhou S, Lee MH, Naik A, Chang CM, Garfinkel A, et al. Effects of amiodarone on wave front dynamics during ventricular fibrillation in isolated swine right ventricle. Am J Physiol Heart Circ Physiol 2002; 282: H1063-H1070.
6. Riccio ML, Koller ML, Gilmour RF Jr. Electrical restitution and spatiotemporal organization during ventricular fibrillation. Circ Res 1999; 84: 955-963.
7. Wu TJ, Lin SF, Weiss JN, Ting CT, Chen PS. Two types of ventricular fibrillation in isolated rabbit hearts: Importance of excitability and action potential duration restitution. Circulation 2002; 106: 1859-1866.
8. Koller ML, Maier SK, Gelzer AR, Bauer WR, Meesmann M, Gilmour RF Jr. Altered dynamics of action potential restitution and alternans in humans with structural heart disease. Circulation 2005; 112: 1542-1548.
9. Taggart P, Sutton P, Chalabi Z, Boyett MR, Simon R, Elliott D, et al. Effect of adrenergic stimulation on action potential duration restitution in humans. Circulation 2003; 107: 285-289.
10. Tanaka H, Kinoshita O, Uchikawa S, Kasai H, Nakamura M, Izawa A, et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2001; 24(8 Pt 1): 1293-1294.
11. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 2004; 27(6 Pt 1): 821-823.
12. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 698-701.
13. Murakami M, Nakamura K, Kusano KF, Morita H, Nakagawa K, Tanaka M, et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol 2010; 56: 389-395.
14. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860.
15. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: Report of the second consensus conference. Heart Rhythm 2005; 2: 429-440.
16. Masaki R, Watanabe I, Nakai T, Kondo K, Oshikawa N, Sugimura H, et al. Role of signal-averaged electrocardiograms for predicting the inducibility of ventricular fibrillation in the syndrome consisting of right bundle branch block and ST segment elevation in leads V1-V3. Jpn Heart J 2002; 43: 367-378.
17. Franz MR. Method and theory of monophasic action potential recording. Prog Cardiovasc Dis 1991; 33: 347-368.
18. Ashino S, Watanabe I, Kofune M, Nagashima K, Ohkubo K, Okumura Y, et al. Abnormal action potential duration restitution property in the right ventricular outflow tract in Brugada syndrome. Circ J 2010; 74: 664-670.
19. Kofune M, Watanabe I, Ashino S, Ohkubo K, Okumura Y, Kofune T, et al. Action potential alternans in the right ventricular outflow tract in a patients with asymptomatic Brugada syndrome. Circ J 2009; 73: 580-583.
20. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092-3096.
21. Brugada R, Brugada J, Antzelevitch C, Kirsch G, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal heart. Circulation 2000; 101: 510-515.
22. Pak HN, Hong SJ, Hwang GS, Lee HS, Park SW, Ahn JC, et al. Spatial dispersion of action potential duration restitution kinetics is associated with induction of ventricular tachycardia/fibrillation in humans. J Cardiovasc Electrophysiol 2004; 15: 1357-1363.
23. Selvaraj RJ, Picton P, Nanthakumar K, Chauhan VS. Steeper restitution slopes across right ventricular endocardium in patients with cardiomyopathy at high risk of ventricular arrhythmias. Am J Physiol Heart Circ Physiol 2007; 292: H1262-H1268.
24. Ohkubo K, Watanabe I, Takagi Y, Okumura Y, Ashino S, Kofune M, et al. Endocardial electrograms from the right ventricular outflow tract after induced ventricular fibrillation in patients with Brugada syndrome. Circ J 2007; 71: 1258-1262.
25. Ohkubo K, Watanabe I, Okumura Y, Ashino S, Kofune M, Ohta M, et al. Surface ECG characteristics of ventricular tachycardias before degenerating into ventricular fibrillation in patients with Brugadatype ECG. Int Heart J 2009; 50: 477-487.
26. Park SW, Kim YH, Park SM, Rha SW, Ahn JC, Lim DS, et al. Relation between action potential restitution kinetics and inducibility of ventricular fibrillation in Brugada syndrome (abstract). Pacing Clin Electrophysiol 2003; 26(Part II): S24.
27. Qu Z, Weiss JN, Garfinkel A. Cardiac electrical restitution properties and stability of reentrant spiral waves: A simulation study. Am J Cardiol 1999; 276: H269-H283.
28. Karma A. Electrical alternans and spiral wave breakup in cardiac tissue. Chaos 1994; 4: 461-472.
29. Bass BG. Restitution of the action potential in cat papillary muscle. Am J Physiol 1975; 228: 1717-1724.
30. Veldkamp MW, Viswanathan PC, Bezzina C, Baartscheer A, Wilde AA, Balser JR. Two distinct congenital arrhythmias evoked by a multifunctional Na(+) channel. Circ Res 2000; 86: E91-E97.
31. Wang DW, Makita N, Kitabatake A, Balser JR, George AL Jr. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome. Circ Res 2000; 87: E37-E43.
32. Imaizumi Y, Giles WR. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 1987; 253(3 Pt 2): H704-H708.
33. + channel currents by quinidine. Circ Res 1993; 73: 351-359.
34. Kasanuki H, Ohnishi S, Matsuda N, Nirei T, Isogai R, Shoda M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95: 2277-2285.
35. Mizimaki K, Fujiki A, Tsuneda T, Sakabe M, Nishida K, Sugao M, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15: 667-673.
36. Nakajima T, Kurachi Y, Ito H, Takikawa R, Sugimoto T. Anticholinergic effects of quindine, disopyramide, and procainamide in isolated atrial myocytes: Mediation by different mechanisms. Circ Res 1989; 64: 297-303.
37. Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: Quinidine as an alternative to ICD therapy. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, editors. The Brugada syndrome: From bench to bedside. Oxford: Blackwell Futura, 2004; 202-211.
38. Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. Handb Exp Pharmacol 2006; 171: 305-330.
39. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262: 99-108.
40. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells: Concentration-time-, voltage-, and use-dependent effects. Circulation 1995; 91: 1799-1806.
41. Lynch JJ Jr, Baskin EP, Nutt EM, Guinosso PJ Jr, Hamil T, Salata JJ, et al. Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995; 25: 336-340.
42. Oshikawa N, Watanabe I, Masaki R, Shindo A, Kojima T, Saito S, et al. Frequency-dependent electrophysiological effect of ibutilide on human atrium and ventricle. J Interv Card Elecrophysiol 2001; 5: 81-87.